How to Code Neoplasms — Benign, Malignant, Uncertain Explained

Neoplasm coding is one of the most challenging areas in ICD-10-CM. Unlike many other conditions where one code captures the complete clinical picture, neoplasm coding requires you to evaluate the behavior of the tumor, the anatomical site, whether it has spread, why the patient is being seen today, and whether the neoplasm is still active or part of personal history. Each of these factors changes which code — and sometimes which sequence of codes — is correct.

This guide breaks down the ICD-10-CM Neoplasm Table, explains the six behavior columns, walks through sequencing rules for primary and secondary malignancies, and covers the treatment encounter codes that appear frequently on the CPC exam.

The Neoplasm Table — Six Behavior Columns

The ICD-10-CM Neoplasm Table is organized by anatomical site (rows) and tumor behavior (columns). Every neoplasm code assignment starts with identifying the correct column:

The column you choose is determined by the pathology report, not by clinical suspicion. A physician may suspect malignancy, but until pathology confirms it, you cannot assign a malignant code. If the biopsy results are pending, code the signs and symptoms that prompted the workup — not the suspected neoplasm.

Malignant Primary vs. Secondary — The Sequencing Rules

When a cancer has metastasized, the patient has at least two neoplasm codes: one for the primary site and one or more for the secondary (metastatic) site(s). Sequencing rules determine which code is listed first, and the answer depends entirely on the reason for the encounter.

Rule 1 — Treatment Directed at the Primary Site

When the encounter is for treatment of the primary malignancy, the primary neoplasm code is sequenced first. Even if metastatic disease exists, the primary site code is the principal or first-listed diagnosis because that is the reason for the visit.

Clinical Example: Patient with lung cancer that has metastasized to the brain presents for chemotherapy directed at the lung cancer. Correct sequencing: C34.90 (primary malignant neoplasm of lung) is listed first. C79.31 (secondary malignant neoplasm of brain) is listed as an additional diagnosis.

Rule 2 — Treatment Directed at the Secondary Site

When the encounter is for treatment of the metastatic (secondary) site, the secondary neoplasm code is sequenced first. The primary site code is listed as an additional diagnosis.

Clinical Example: Same patient presents for surgical resection of the brain metastasis. Correct sequencing: C79.31 (secondary malignant neoplasm of brain) is listed first. C34.90 (primary malignant neoplasm of lung) is listed as an additional diagnosis.

Rule 3 — Treatment Directed at Both Sites

When both the primary and secondary sites are being treated during the same encounter, either code may be sequenced first.

Rule 4 — Primary Site Unknown

When a patient presents with metastatic disease and the primary site is unknown or has been eradicated, assign C80.1 (malignant neoplasm, unspecified site — primary site unknown). The secondary site codes are assigned as additional diagnoses.

Carcinoma in Situ — D00–D09

Carcinoma in situ (CIS) describes abnormal cells that look like cancer under the microscope but have not broken through the basement membrane to invade surrounding tissue. It is a critical distinction because CIS is coded differently from invasive malignancy and has a different prognosis and treatment pathway.

CIS codes range from D00 to D09, organized by anatomical site. CIS of the cervix (D06.-) is one of the most commonly coded CIS diagnoses. CIS is sometimes called “stage 0” cancer, but it is not coded with a C code — it gets its own D00–D09 category.

Clinical Example: Pathology from a cervical biopsy shows cervical intraepithelial neoplasia grade III (CIN III), which is classified as carcinoma in situ. Correct code: D06.9 (carcinoma in situ of cervix, unspecified). This is NOT coded as C53.- (malignant neoplasm of cervix).

Benign Neoplasms — D10–D36

Benign neoplasms are non-cancerous growths that do not invade surrounding tissue or metastasize. They are coded from D10–D36 based on anatomical site. Common examples include uterine leiomyomas (fibroids), lipomas, and colon polyps confirmed as adenomas.

Benign neoplasms generally require only a single code for the site. They do not have primary/secondary sequencing logic because they do not metastasize.

Clinical Example: A patient presents for excision of a lipoma of the back. The pathology report confirms benign lipoma. Correct diagnosis code: D17.1 (benign lipomatous neoplasm of trunk).

Treatment Encounter Codes — Z51

When a patient presents specifically for cancer treatment — chemotherapy, radiation therapy, or immunotherapy — the treatment encounter code from Z51 is sequenced FIRST, and the neoplasm code is listed as an additional diagnosis. This is a critical sequencing rule tested heavily on the CPC exam.

Clinical Example: Patient with colon cancer presents to the infusion center for a scheduled chemotherapy session. Correct sequencing: Z51.11 (encounter for chemotherapy) listed first, then C18.9 (malignant neoplasm of colon, unspecified) as additional diagnosis.

Complications During Treatment

If a patient develops a complication during a treatment encounter (such as severe nausea during chemotherapy that requires management), the complication code may be sequenced first if it becomes the primary reason for the visit. The treatment encounter code and neoplasm code are then listed as additional diagnoses. This follows the general guideline that the condition requiring the most resources is the principal diagnosis.

Neoplasm-Related Anemia

When a patient has anemia due to a malignancy, the sequencing depends on the reason for the encounter. If the encounter is primarily for treatment of the anemia (such as a blood transfusion), code D63.0 (anemia in neoplastic disease) first, followed by the neoplasm code. If the encounter is primarily for treatment of the malignancy and anemia is also present, sequence the neoplasm code first and D63.0 as an additional diagnosis.

This is the same encounter-driven sequencing logic that applies throughout neoplasm coding — the reason for the visit determines the first-listed diagnosis.

Personal History of Neoplasm — Z85

When a primary malignancy has been excised or eradicated and the patient is no longer receiving active treatment, the neoplasm code is no longer assigned. Instead, use a code from Z85.- (personal history of malignant neoplasm) to document the history. These Z codes are important because they affect screening recommendations, follow-up schedules, and clinical decision making.

Clinical Example: Patient had a mastectomy for breast cancer two years ago. She has completed all treatment and is now cancer-free, presenting for a routine follow-up mammogram. Correct coding: Z85.3 (personal history of malignant neoplasm of breast) + Z12.31 (encounter for screening mammogram).

Coding Neoplasms of Uncertain and Unspecified Behavior

Uncertain behavior (D37–D48) is assigned when the pathologist has examined the tissue and cannot definitively classify it as benign or malignant. This is a pathological determination — the tissue is ambiguous under microscopic examination.

Unspecified behavior (D49) is assigned when the documentation does not state the behavior of the neoplasm. This is a documentation issue, not a pathological one. The coder should query the provider for clarification whenever possible rather than defaulting to D49.

Neither uncertain nor unspecified behavior codes have primary/secondary columns because those concepts apply only to malignant neoplasms. A tumor must be confirmed as malignant before you can classify it as primary or secondary.

Neoplasm Coding Decision Framework

Step 1 — Identify the behavior. Is the neoplasm malignant, benign, in situ, uncertain, or unspecified? This determines which column of the Neoplasm Table (or which code range) to use. Always base the behavior on pathology results, not clinical suspicion.

Step 2 — Identify the anatomical site. Locate the site in the Neoplasm Table. Be as specific as the documentation allows. “Lung” is less specific than “upper lobe of right lung.”

Step 3 — For malignant neoplasms, determine primary vs. secondary. If the cancer originated at this site → primary (C00–C76, C80). If the cancer spread to this site from elsewhere → secondary (C77–C79).

Step 4 — Determine sequencing based on encounter purpose. Treatment directed at primary → primary code first. Treatment directed at secondary → secondary code first. Chemo/radiation/immunotherapy session → Z51 first, then neoplasm. Follow-up with no active disease → Z85 history code.

Step 5 — Assign all additional codes. Include codes for secondary sites, treatment complications, anemia (D63.0), and any other coexisting conditions documented. This is where understanding combination codes helps you avoid over-coding conditions that are already captured in a single code.

Connections to Other Coding Topics

Neoplasm coding intersects with several other ICD-10 concepts. The medical terminology guide covers roots like “onco-” (tumor), “-oma” (tumor/neoplasm), “carcin/o” (cancer), and “sarc/o” (connective tissue cancer) that appear throughout neoplasm documentation. Understanding ICD-10 sequencing rules is essential because neoplasm coding depends more heavily on encounter-based sequencing than almost any other topic. And the diabetes coding guide provides a useful comparison — both neoplasms and diabetes require coding the underlying condition plus its manifestations.

Frequently Asked Questions